SLCO4A1 is a Prognosis-Associated Biomarker Involved in Neutrophil-Mediated Immunity in Thyroid Cancer

Wang, Xin-SHeng; Wu, Shile; Peng, Zhe; Zhu, Haihong

doi:10.2147/ijgm.s339921

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, SLCO4A1 overexpression was associated with a shorter OS or DFS ( Figure 3 ). Interestingly, our results are similar to those of some studies, but the role of SLCO4A1 in the occurrence and development of COAD still needs to be further researched [ 48 , 49 ].…”

Section: Discussionsupporting

confidence: 90%

“…Previous studies have shown that abnormalities of the SLCO4A1 gene have multifaceted 9 Mediators of Inflammation effects for many tumors. Overexpression of the SLCO4A1 gene in prostate cancer and thyroid cancer indicated a poor prognosis [48,50]. Buxhofer-Ausch et al have shown that SLCO4A1 may affect the accumulation of anticancer drugs in specific cancer cells [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma

Chen

Zhou

et al. 2023

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Solute carrier organic anion transporter family member 4A1 (SLCO4A1), a member of solute carrier organic anion family, is a key gene regulating bile metabolism, organic anion transport, and ABC transport. However, the association of SLCO4A1 with prognosis and tumor immune infiltration in colon adenocarcinoma (COAD) remains indistinct. Methods. Firstly, we explored the expression level of SLCO4A1 in COAD via GEPIA, Oncomine, and UALCAN databases. Secondly, we used the Kaplan-Meier plotter and PrognoScan databases to investigate the effect of SLCO4A1 on prognosis in COAD patients. In addition, the correlation between SLCO4A1 and tumor immune infiltration was studied by using TIMER and TISIDB databases. Results. Our results showed that SLCO4A1 was overexpressed in COAD tissues. At the same time, our study showed that high expression of SLCO4A1 was associated with poor overall survival, disease-free survival, and disease-specific survival in COAD patients. The expression level of SLCO4A1 was negatively linked to the infiltrating levels of B cells, CD8+ T cells, and dendritic cells in COAD. Moreover, the expression of SLCO4A1 was significantly correlated with numerous immune markers in COAD. Conclusions. These results indicated that SLCO4A1 could be associated with the prognosis of COAD patients and the levels of tumor immune infiltration. Our study suggested that SLCO4A1 could be a valuable biomarker for evaluating prognosis and tumor immune infiltration in COAD patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma

Chen

Zhou

et al. 2023

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…The expression of Human β-defensin 1 (encoded by DEFB1) was found to be associated with Hp infection, while the mechanisms by which DEFB1 achieved its effects in GC remained unclear [49,50]. In contrast to our ndings, most studies indicated the elevated expression of SLCO4A1 might facilitate the progression of cancer, because they found that SLCO4A1 mediated the cellular uptake of many substrates including hormones, which regulated the progression of cancer through binding the hormone receptors [51][52][53]. It was possible that SLCO4A1 mediated the cellular uptake of estrone-sulfate and dehydroepiandrosteronesulfate in GC, which were the most important estrogen precursors in the plasma of postmenopausal females [53].…”

Section: Discussioncontrasting

confidence: 73%

Molecular characteristics, potential mechanisms and prognostic gene model of younger female patients with gastric cancer

Luan,

Zhao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Male patients were twice as likely to develop gastric cancer (GC) compared to females, partly due to the protective effect of estrogen. However, the proportion of females increased in the young GC patients. The study was designed to explore comprehensive molecular profiles of younger female GC patients, as well as develop a prognostic gene model for female GC patients. Methods Gene expression and clinical data of GC and non-tumor patients were downloaded from the Gene Expression Omnibus (GEO) database. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were used to find molecular characteristics and potential mechanisms of younger female GC patients. The prognostic gene model containing 6 differential expressed genes (DEGs), which were between younger and older female patients, was established using Lasso-Cox regression. Its performance was validated by external validation. Then, receiver operating characteristic (ROC) curve was applied to determine the prognostic value of the prognostic gene model. Results Six GEO cohorts with 305 female GC patients (69 younger patients and 236 older patients) and 38 female non-tumor patients were included. A total of 4557 DEGs between female GC patients and non-tumor patients were identified, including 2212 up-regulated genes and 2345 down-regulated genes. Estrogen response early (p < 0.001) and estrogen response late (p < 0.001) were enriched in female GC patients. In KEGG analysis, aldosterone (p = 0.023) and relaxin pathways (p = 0.043) were concentrated in younger group. Moreover, we further used GSE84437 cohort to construct a prognostic gene model containing 6 genes, namely NREP, GAD1, SLCO4A1, KRT17, DEFB1, and P3H2, to predict the overall survival (OS) of female GC patients (AUC = 0.810). Younger female patients, who were related with high-risk at the genetic level, showed worse OS compared with older female patients who showed low-risk (HR = 5.7688, 95%CI: 3.0108–11.0530, P < 0.001). Conclusions In conclusion, we provided the comprehensive molecular profiles of younger female GC patients and found that there was a significant difference in enriched hormone-related pathways between younger group and older group. In addition, we found younger female patients showed worse OS compared with older female patients using the prognostic gene model we created.

show abstract

“…It has been demonstrated that abnormalities in SLCO4A1 have diverse impacts on various tumors. Increased expression of SLCO4A1 in prostate and thyroid cancer has been associated with an unfavorable prognosis (28,29). A previous study indicated that SLCO4A1 may influence the accumulation of anticancer drugs in specific cancer cells, thereby exerting an antitumor effect (30).…”

Section: Discussionmentioning

confidence: 99%

SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration

Li,

Huang

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

SLCO4A1 is a Prognosis-Associated Biomarker Involved in Neutrophil-Mediated Immunity in Thyroid Cancer

Cited by 7 publications

References 25 publications

Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma

Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma

Molecular characteristics, potential mechanisms and prognostic gene model of younger female patients with gastric cancer

SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration

Contact Info

Product

Resources

About